title: Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Wenn
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Tomala
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Wilop
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Vankann
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Hasenbank
authors.affiliation: Novartis Pharma GmbH, Nürnberg, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Frank
authors.affiliation: Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.affiliation: Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.
authors.forename: F J
authors.initials: FJ
authors.lastname: Giles
authors.affiliation: Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Lange
authors.affiliation: Department of Hematology/Oncology, Universitätsmedizin Mannheim, Germany.
authors.forename: M C
authors.initials: MC
authors.lastname: Müller
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Koschmieder
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Beier
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.|Institute for Occupational and Social Medicine, Aachen University, Aachen, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Ziegler
authors.affiliation: Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
authors.forename: T H
authors.initials: TH
authors.lastname: Brümmendorf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D016615:Telomere
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib